Success Metrics

Clinical Success Rate
28.6%

Based on 2 completed trials

Completion Rate
29%(2/7)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
5(56%)

Phase Distribution

Ph phase_1
3
33%
Ph phase_2
6
67%

Phase Distribution

3

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

28.6%

2 of 7 finished

Non-Completion Rate

71.4%

5 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(2)
Terminated(5)
Other(2)

Detailed Status

Terminated5
unknown2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
28.6%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (33.3%)
Phase 26 (66.7%)

Trials by Status

unknown222%
terminated556%
completed222%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_2

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)

NCT04927169
terminatedphase_2

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

NCT04407689
terminatedphase_2

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort

NCT04379076
completedphase_2

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT02640807
terminatedphase_2

Immune Reconstitution of Immunosuppressed Sepsis Patients

NCT02797431
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04927169Phase 2

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)

Terminated
NCT04407689Phase 2

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

Terminated
NCT04379076Phase 2

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort

Terminated
NCT02640807Phase 2

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

Completed
NCT02797431Phase 2

Immune Reconstitution of Immunosuppressed Sepsis Patients

Terminated
NCT01190111Phase 2

Study on Interleukin-7 (CYT107) in HIV Patients

Terminated
NCT01024894Phase 1

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy

Unknown
NCT01025297Phase 1

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone

Unknown
NCT01025596Phase 1

Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9